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LMICsA B S T R A C T
Pneumonia is a leading cause of mortality in limited resource settings (LRS), which are
common in low- and middle-income countries (LMICs). Accurate referrals can reduce the
devastating impact of pneumonia, especially in LRS. Discriminating pneumonia from other
respiratory conditions based only on symptoms is a major challenge. Machine learning has
shown promise in overcoming the diagnostic difficulties of pneumonia (i.e., low specificity
of symptoms, lack of accessible diagnostic tests and varied clinical presentation). Many sci-
entific papers are now focusing on deep-learningmethods applied to clinical images, which
is unaffordable for initial patient referral in LMICs. The current study used a dataset of 4500
patients (1500 patients affected by bronchitis, 3000 by pneumonia) from a middle-income
country, containing information on subject population characteristics, symptoms and lab-
oratory test results. Manual feature selection was performed, focusing on clinical symp-
toms that are easily measurable in LRS and in community settings. Three common
machine learning methods were tested and compared: logistic regression; decision tree
and support vector machine. Models were developed through a holdout process of
training-validation and testing. We focused on six clinically relevant, easily interpreted
patient symptoms as best indicators for pneumonia. Our final model was a decision tree,
achieving an AUC of 93%, with the advantage of being fully intelligible and easily inter-ineering of
ity Health
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enhance symptom-based referral of pneumonia in LRS and in community settings.
 2021 The Authors. Published by Elsevier B.V. on behalf of Nalecz Institute of Biocybernetics
and Biomedical Engineering of the Polish Academy of Sciences. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Pneumonia has a devastating impact on global health and is
the largest cause of death due to infection in children world-
wide [1]. Although cases of pneumonia are found globally, the
disease burden falls heavily in low- and middle income coun-
tries (LMICs), with around 90% of the global child mortality
due to pneumonia and diarrhoea occurring in sub-Saharan
Africa and South Asia [2]. Characteristics of individuals living
in LMICs, such as malnutrition and exposure to air pollution,
have long been understood to increase susceptibility to severe
pneumonia [3]. Further to this, the access to appropriate
treatment can be problematic in many LMICs, further increas-
ing pneumonia fatalities. Fundamental to reducing deaths is
rapid identification of the most appropriate treatment for
pneumonia, as recognised in the 2015 Global Action Plan for
the Prevention and Control of Pneumonia and Diarrhoea
(GAPPD) [2], which calls for an end to preventable child deaths
from pneumonia by 2025.
Once the patient is referred to specialised hospitals with
suspected pneumonia, a confirmed diagnosis requires instru-
mental diagnostic tests (e.g., X-ray, pulse oximetry, blood
tests and sputum tests), often integrated with more advanced
investigations (e.g., CT scan, arterial blood gas tests, pleural
fluid culture and bronchoscopy) [4,5]. Those tests and investi-
gations are costly and not widely available in LMIC commu-
nity settings, especially in rural areas. Unfortunately,
pneumonia signs and symptoms are common to many other
respiratory diseases (e.g., bronchitis), resulting in incorrect or
delayed referrals. In fact, pneumonia signs and symptoms
include cough (often with mucus and blood production), dys-
pnoea, fever, sweating, chest pain, loss of appetite, fatigue,
nausea and vomiting (sometimes with mucus and blood)
and confusion, especially in senior patients.
Accurate and timely pneumonia referral is crucial, espe-
cially in limited resource settings (LRS), which are abundant
in LMICs [6]. The meaning of LRS may differ depending on
the context [7], here LRS are taken to describe a healthcare
setting experiencing a lack of either physical or organiza-
tional infrastructure, such as trained personal, facilities or
equipment [6]. The COVID-19 pandemic demonstrated that
appropriate referral of pneumonia is crucial also in high-
income countries during a disaster, such as a pandemic [8].
For instance, the number of papers retrieved in PubMed com-
bining the keywords ‘‘pneumonia” and ‘‘referral” moved from
approximately 13 papers per month in 2019 to 90 papers per
month in 2020 and 136 papers per month in 2021 until March
(search query ‘‘(referral) AND (pneumonia)” in PubMed; search
date 6th of April 2021).The availability of large datasets and the need for highly
accurate and timely referral and detection of diseases are
motivating the use of data-driven machine learning (ML)
methods in the field [9-11]. ML and deep learning methods
have gained much attention in recent years for the automatic
detection of pneumonia through imaging, in particular
through analysis of chest X-ray or computed tomography
(CT) [12-20]. The onset of COVID-19 and the subsequent global
pressure on healthcare systems has further driven research in
this area [21-24]. Such techniques are an attractive way to
reduce the pressure on healthcare services with limited med-
ical resources and staff, by providing fast and accurate diag-
nosis, reducing demand on equipment and expertise.
Important considerations for use in LRS are speed of classifi-
cation and minimal user input and energy requirements [12].
Although these methods are crucial for diagnosing pneumo-
nia in a hospital setting, it is important to also consider that
barriers exist in LMICs, which delay the diagnosis of pneumo-
nia. In this regard, it is crucial to also support disease referrals
in community settings, where symptoms alone can be
assessed. In fact, it is widely accepted that identification
and management of pneumonia in community settings sig-
nificantly reduces deaths [25]. Healthcare services in LMICs
strongly rely on community health workers (CHWs), espe-
cially in rural areas where there is inconsistent access to spe-
cialised doctors or hospitals [26]. Evidence suggested that
Rapid Diagnostic Tests (RDTs) may support CHWs in detecting
pneumonia in community settings [27,28]. Such an approach
has proved promising in increasing quality of care and
improving diagnosis and treatment availability especially in
LRS [29], where patients may gain access to diagnostic sys-
tems using widely available technology such as smart phones
[30]. Yet, there is a clear gap in interpreting pneumonia symp-
toms, which may be bridged through integration of RDTs and
smart phones with ML, especially in community settings.
This remains challenging due to the similarity of pneumonia
symptoms with those of other respiratory diseases, such as
bronchitis. In fact, different lower-respiratory-tract diseases
tend to present with an overlapping set of symptoms, in this
way it may be difficult to manually identify patterns and fea-
tures in data, making it another appropriate challenge to be
faced with ML. Unfortunately, this problem has not been well
investigated. In fact, from the existing literature, it can be
found that use of traditional ML for lower-respiratory-
disease recognition based on symptoms is relatively scarce.
This is limiting the potential for implementation of ML mod-
els in clinical analysis, which could improve the diagnostic
capability of existing Computer-Aided Design (CAD) systems
to automatically detect diseases such as pneumonia [31].
Fig. 1 – A workflow of all major steps taken in this work.
Initially raw data was cleaned i.e., to deal with missing data
and analyse outliers. Statistical analysis was performed to
evaluate possible heterogeneity of population
characteristics and variable distribution between patient
groups. Initial manual feature choice on the clean dataset
was completed before data splitting into separate folders.
Feature selection was done by using backwards feature
selection during the ML model training and validation.
Model testing was performed on Folder 2. Finally,
performance of the models on the test data folder was
evaluated using several metrics recommended by the
literature.
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pneumonia referral, especially when resources and expertise
are not widely available such as in LMICs and LRS. Correct
referral holds the key to the most effective diagnosis, treat-
ment and management [32]. In particular, pneumonia and
bronchitis have many similar symptoms, affecting patients’
referral. Indeed, where pneumonia refers to the presence of
fluid in the alveoli, bronchitis is characterized by acute
inflammation of the trachea and airways. Bronchitis most
commonly results from viral infection, therefore, treatment
with antibiotics is not generally effective, whereas for pneu-
monia the situation is reversed, providing strong motivation
for correct referrals [17,33].
Several studies have achieved promising performance in
classification of pneumonia [34-43] and other respiratory dis-
ease such as Chronic Obstructive Pulmonary Disease (COPD)
and asthma [44-46] using ML with symptomatic predictors
in combination with laboratory test results. However, there
has been relatively little investigation of models using purely
symptoms and signs as predictors [47,48], which, given the
restraints upon healthcare at the community level, highlights
a shortfall of research in this area. Furthermore, several
issues in the field are apparent: reports do not provide a
strong evidence base for their models, there is a lack of clarity
in reporting of ML methods and the issue of distinguishing
pneumonia from other similarly presenting respiratory dis-
eases is not addressed in the existing literature.
Therefore, this study aimed to design an evidence based
and interpretable ML model, using easily recognized
symptoms and signs as predictors, which can distinguish
between patients with bronchitis and pneumonia. Such a
model is suitable for incorporation into a diagnostic tool, for
the purpose of screening for pneumonia in the
community, with the aim of improving access to referral
and treatment.
2. Materials and methods
The steps completed during this work, beginning with the
raw data and ending with an evaluation of predictive model
performance, are outlined in Fig. 1. Symptomatic features
were manually considered for machine learning in accor-
dance with their clinical relevance and the goals of this study.
A full description of the dataset and further details of each
stage in the analysis are provided in the following sections.
2.1. Dataset
The data used in this work was collected as part of a prospec-
tive study, following internationally accepted medical prac-
tices for diagnosis of Chronic obstructive pulmonary disease
(COPD) and asthma [49,50]. The dataset was generated to be
suitable for design, validation, and real-time testing of a clas-
sifier to automatically identify bronchitis and pneumonia.
Before starting the study, the ethics board approval for human
subject testing from the Hospital Sarajevo was obtained (No.
01-11/EO-06/18), as well as the patients’ informed consent.Healthcare institutions also approved all methods and proce-
dures which were performed in accordance with the relevant
guidelines and regulations. Samples originate from the period
of October 2017 until December 2018.
Only patients with confirmed diagnosis were included as
subjects in this study. Diagnoses were performed by medical
professionals following clinical assessment according to
international guidelines. Baseline assessments consisted of
screening for patient symptoms using symptom-based ques-
tionnaires or interviews conducted by a medical professional.
All spirometry lung function tests were obtained using the
CareFusion ‘‘Master Screen” device (Hoechberg, Germany),
which measured, derived and calculated all the required
spirometry parameters.
The dataset comprised clinical information on 4500 indi-
viduals either diagnosed with bronchitis (1500) or pneumonia
(3000). Information collected included a range of symptoms
typical of respiratory illness, laboratory test results and vari-
ous population descriptive characteristics such as exposure
to air pollution or malnutrition. This information was estab-
lished by medical professionals. Full description of the vari-
ables extracted are presented in Table 1.
Table 1 – Description of categorical and continuous variables present in dataset with different possible levels where appro-
priate for: multiclass and binary variables.
Sign and symptoms (Multiclass) Description
























Sign and symptoms (binary)
Associated diseases Did the patient have any other associated diseases (yes or no)
Immunosuppression Was immunosuppression present in patient (yes or no)
Allergy Any allergies present in patient (yes or no)
Exposure to air pollution Was the patient likely to be exposed to air pollution (probable or no)
Malnutrition Did the patient suffer malnutrition
Cough Did the patient have a cough (yes or no)
Expectoration Did the patient have expectoration (yes or no)
Dyspnoea Did the patient have dyspnoea (yes or no)
Pleura Pain Did the patient have pleura pain (yes or no)
Fever Did the patient have a fever (yes or no)
Sweating Did the patient have sweating (yes or no)
Muscle pain Did the patient have muscle pain (yes or no)
Headache Did the patient have a headache (yes or no)
Loss of appetite Did the patient have a loss of appetite (yes or no)
Laboratory test results
Sedimentation Measure of sedimentation of red blood cells.
Fibrinogen Blood coagulation factor
CRP (mg/ml) Indicative of inflammation or infection
Leukocytes Total white blood cell count
Neutrophils Subtype of white blood cell
Lymphocytes Subtype of white blood cell
Monocytes Subtype of white blood cell
Basophils Subtype of white blood cell
Eosinophils Subtype of white blood cell
Spirometry Measure of amount and/or speed of air that can be inhaled and exhaled.
Parameter measured: Volume expelled in one breath relative to expected reference,
Forced Vital Capacity (FVC, %)
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Statistical analysis was used to determine whether there was
homogeneity between patients with pneumonia and bronchi-
tis in terms of age, sex, and population characteristics. Fur-
ther statistical tests were employed to understand the
behavior of variables in terms of their distribution i.e.,
whether continuous variables were normally distributed.
Finally, statistical differences of variables between the two
patient groups were evaluated. Statistical test selection was
informed by best practice guidelines described in the litera-
ture [51] and the methodology of the identified similar studies
[34-42,52].
Features were tested for normality using the Chi-square
goodness of fit test. Continuous variables were expressed as
mean ± standard deviation or median and standard error. A
non-parametric statistical test, Kruskal–Wallis test, was used
for comparison of continuous variables between the two
groups of patients (pneumonia and bronchitis), as it is appro-
priate for variables which are not normally distributed [51].
Categorical variables were expressed as a percentage and
were compared using the Chi-Square, or Fisher Exact tests.
A p-value of <0.05 was considered significant when assessing
the variation of the features among the two patient groups.
Bonferroni’s correction was used for multiple hypothesis cor-
rection if necessary. Correlation analysis was carried out by
Goodman and Kruskal’s tau correlation.
Box and scatter plots were used to identify outliers in con-
tinuous variables. After ensuring that there were no changes
to the data on importing or coding, outliers were quantified as
any value which is more than three scaled absolute devia-
tions from the median [53]. Subjects with outlying continuous
variable values (156 individuals) were removed from the data-
set, leaving 2844 pneumonia and 1500 bronchitis subjects. All
the analyses were run in Matlab2019b.
2.3. Model training, validation, and testing procedure
As shown in Fig. 2, training and validation was performed on
Folder 1 (60% of the total amount of data), and testing wasFig. 2 – Feature selection, training and testing of machine learnin
machine learning model.performed on the remaining independent 40 % of data. The
splitting was done in a stratified subject-wise fashion.
Feature Selection. Sufficiently large numbers of subjects
allowed free selection amongst available attributes, comply-
ing with the ’10 events per attribute’ rule of thumb to avoid
overfitting [9,54]. In the event that there were zero occur-
rences of a certain symptom in either class, these symptoms
were discarded due to risk that information was not collected
and to avoid a trivial separation of groups. Initial manual fea-
ture choice was performed on the clean dataset based on clin-
ical relevance. In fact, for a diagnostic and/or screening
application, the features should have some bearing on the
disease [55]. Feature selection, based on the cluster of features
manually selected, was then performed on Folder 1, after data
splitting. Therefore, feature selection and model training
were performed on the same folder [56]. Correlations between
variables was evaluated using Kendall rank correlation test,
with correlating variables not to be included as features. Cor-
related variables were considered as those which had a statis-
tically significant Kendall rank coefficient greater than 0.5
( sj j > 0:5; p < 0:05). Backward feature selection was per-
formed on the training dataset with only the best combina-
tion of features reported on.
Machine Learning Methods. Models automatically classifying
patients as either having bronchitis or pneumonia were
developed using three different machine learning methods:
logistic regression (LR), decision tree and support vector
machine (SVM). LR is an extension of linear regression, which
predicts probability of a case belonging to a certain class [57].
A decision tree creates a set of ‘if-else’ conditions to predict
the class of a given case [58]. SVM, which belongs to a general
field of kernel-based machine learning methods, is used to
efficiently classify both linearly and nonlinearly separable
data [59]. Algorithm parameter tuning was performed during
training and validation. Regarding the final model parame-
ters, a fine tree with maximum splits of 100 was used for
the decision tree, while a linear kernel with a scale of 0.8792
was used for SVM.
Training and validation. The training of the machine-
learning models was performed on the folder 1 (1706 pneu-gmethods. This diagram shows the workflow to develop the
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into ten equal sized subsamples, according to the 10- fold
person-independent cross-validation approach. Of these ten
subsamples, nine subsamples were used as training data
and the remaining one was retained for validating the model.
The process was then repeated ten times, with each of the ten
subsamples used exactly once as the validation data. Finally,
the cross-validated estimations were computed by averaging
the performances over the ten validation subsamples. Classi-
fication measures were adopted according to the standard
formulae [60].
Testing. Testing a classifier involves analyzing its perfor-
mance on a set of subjects that is independent from the train-
ing and validation set [61]. Accordingly, folder 2 (1138
pneumonia patients, 600 bronchitis) was used to test the
trained models.
The model performance was obtained for the optimal
operating point on the receiving operating characteristic
(ROC) curve, as calculated by the MATLAB perfcurve function
that relies on a previously described cost-function curve anal-
ysis [62].
Finally, the best performing model was selected as the one
achieving the highest averaged area under curve (AUC), which
is a reliable estimator of both sensitivity and specificity rates.
In case of equal AUC, the model with the highest overall accu-
racy was selected.
3. Results
The clean dataset consisted of a total of 4344 samples, of
which 2844 patients were diagnosed with pneumonia and
the remaining with bronchitis. All continuous features were
not normally distributed, with p-values <0.01. The mean,
median, standard deviation and range of continuous variables
is shown in Table 2. The final column reports the p-value of
the Kruskal-Wallis Test for attribute variations between bron-
chitis and pneumonia subjects. All p-values fell <0.01, this
indicates significant difference for all attributes between
bronchitis and pneumonia.
The counts and proportions of the categorical variables
between pneumonia and bronchitis groups is presented inTable 2 – Continuous variable statistics across bronchitis and p
Variable Bronchitis
Mean Median SD Range
Age 53.04 52 27.08 93.00
Sedimentation 15.39 15.62 8.70 29.92
Fibrinogen 348.59 343.32 199.21 698.11
CRP (mg/ml) 24.53 25.07 14.52 49.89
Leukocytes 27.00 27.03 13.10 45.96
Neutrophils 11.01 11.08 5.38 18.19
Lymphocytes 5.42 5.34 2.67 9.20
Monocytes 1.90 1.91 0.64 2.20
Basophils 0.15 0.15 0.09 0.30
Eosinophils 1.00 1 0.58 2.00
Spirometry 65.34 65.485 8.92 30.96
Mean, median, standard deviation (SD) and range are reported for pneum
outcome of the Kruskal–Wallis test for variation between pneumonia anTable 3. The final column reports the resulting p-value of
the Chi-square (multi-class attributes) and Fisher Exact (bi-
nary attributes) Tests. Several symptoms were either not reg-
istered during data collection or not experienced by
bronchitis sufferers: fever, sweating, muscle pain, headache
and loss of appetite. Such attributes were discarded as the
clear distinction does not provide an appropriate machine
learning problem. Further, there may have been differences
in data collection between groups for these symptoms. Age
above 65 years old, auscultation, sputum and RTG showed
to be statistically different with a p-value less than 0.01
between bronchitis and pneumonia cases.
Kendal rank correlation analysis between symptoms
(cough, expectoration, dyspnoea, pleura pain, auscultation
and sputum) and population descriptive variables (Above 65,
associated chronic bronchopulmonary, immunosuppression,
allergy, exposure to air pollution) found no correlations. Back-
wards feature selection found that including all the six above
symptoms granted the best model performance. Population
descriptive variables did not improve performance so were
discarded in order to reduce the complexity of the model.
Therefore, the final selected features were: cough, expectora-
tion, dyspnoea, pleura pain, auscultation and sputum. Results
of the three different ML methods are reported in Table 4.
Although AUC are similar across the three methods, the
model considered most successful and suitable was the deci-
sion tree. This is due to its superior overall accuracy over both
LR and SVM. Furthermore, decision tree granted the fastest
execution time to accurately predict pneumonia.
The ROC curves for the final models are shown in Fig. 3.
4. Discussion
This study proposes an easily interpreted, tree-based model
for the automatic classification of pneumonia from bronchitis
based entirely on easily measurable symptoms and signs.
Features were selected based on their clinical relevance and
availability on patient assessment. The manual feature selec-
tion method employed permitted a clear focus on the clinical
utility and application of the model. Some key criteria used
were: i) measurable in a point of care setting [63]; ii) parame-neumonia groups.
Pneumonia
Mean Median SD Range p-value
38.29 36 23.28 100 <0.001
57.78 58 25.11 85 <0.001
706.98 706 173.51 600 <0.001
105.64 106 55.38 190 <0.001
300.19 294.75 168.49 586.4 <0.001
105.76 105.395 52.48 188.86 <0.001
53.15 53.355 27.46 95.45 <0.001
2.98 2.945 1.17 4 <0.001
0.60 0.6 0.23 0.8 <0.001
3.50 3.52 1.44 5 <0.001
57.62 57.87 10.09 34.98 <0.001
onia and bronchitis groups. The p-value reported corresponds to the
d bronchitis groups.
Table 3 – Categorical variable counts and percentages across pneumonia and bronchitis classes.
Variable Bronchitis Count (%) Pneumonia Count (%) p-value
Sex (Female) 764 (50.93) 1398 (49.16) 0.28
Age Above 65 543 (36.20) 417 (14.66) <0.001
Bronchopulmonary chronic Disease present 774 (51.60) 1425 (50.11) 0.35
Other Associated diseases 726 (48.40) 1476 (51.90) 0.03
Immunosuppression 741 (49.40) 1419 (49.89) 0.77
Allergy 769 (51.27) 1397 (49.12) 0.18
Probable exposure to air pollution 713 (47.53) 1440 (50.63) 0.06
Malnutrition 768 (51.20) 1416 (49.79) 0.39
Cough 775 (51.67) 1432 (50.35) 0.42
Expectoration 736 (49.07) 1405 (49.40) 0.85
Dyspnoea 765 (51.00) 1417 (49.82) 0.46
Pleura Pain 764 (50.93) 1428 (50.21) 0.66
Auscultation <0.001
Auscultation 1 377 (25.13) 580 (580 20.39)
Auscultation 2 370 (24.67) 527 (18.53)
Auscultation 3 360 (24.00) 551 (19.37)
Auscultation 4 393 (26.20) 592 (20.82)
Auscultation 5 0 (0) 594 (20.89)
Sputum <0.001
Sputum 1 766 (51.07) 897 (31.54)
Sputum 2 734 (48.93) 977 (34.35)
Sputum 3 0 (0) 970 (34.11)
RTG <0.001
RTG 1 734 (48.93) 347 (12.20)
RTG 2 766 (51.07) 359 (12.62)
RTG 3 0 (0) 347 (12.20)
RTG 4 0 (0) 385 (13.54)
RTG 5 0 (0) 363 (12.76)
RTG 6 0 (0) 357 (12.55)
RTG 7 0 (0) 358 (12.59)
RTG 8 0 (0) 328 (11.53)
The p-value corresponds to the outcome of the chi-square or Fisher Exact tests for variation between pneumonia and bronchitis groups).
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and iv) reliability [34].
The results showed that by using a set of symptoms such
as cough, expectoration, dyspnoea, pleura pain, auscultation
and sputum, the model correctly identified more than 80%
of patients with confirmed diagnosis of pneumonia. Although
cough, expectoration, dyspnoea and pleura pain were not
found to be statistically different among the two classes of
respiratory diseases, the combination of those variables with
auscultation and sputum signs achieved significant results to
automatically distinguish patients affected by pneumonia
from those with bronchitis. These results suggested that it
was possible to correctly distinguish patients presenting with
bronchitis or pneumonia, before performing clinical tests
(e.g., X-ray), which required extensive expertise or advanced
equipment. This can be crucial for patient referrals in com-
munity settings, especially in LRS. In fact, a set of predictors,
which are easily recognised by CHWs or even self-reported
and an automated ML model, which is suitable for incorpora-
tion into a tool such as an APP for use via mobile phones,
would have great value in assisting referrals of pneumonia
in LMICs. Moreover, in high income settings such a tool may
complement traditional community healthcare services by
providing widely available digital tests through apps fortriage. The global need for such technology has been brought
to the forefront of healthcare concerns in particular during
outbreaks of COVID-19.
Although symptoms of bronchitis and pneumonia are sim-
ilar, as discussed in the introduction, the required treatment
is very different. First line treatment for pneumonia generally
comprises antibiotic administration with close monitoring,
while acute bronchitis is self-limiting and does not benefit
from antibiotic treatment [35]. Therefore, there is a high cost
to patient outcomes when these conditions are misdiagnosed
or poorly referred, an easy-to-use tool capable of distinguish-
ing the symptoms of these diseases is desirable.
The use of the symptoms identified in this study is largely
supported by their identification as predictors of pneumonia
by several authors in the literature, using different data and
a variety feature selection methodology. The most commonly
employed predictor from the literature is the outcome of aus-
cultation, of which fast breathing specifically is strongly asso-
ciated with pneumonia [34,36,40-42]. Cough [40,48] and
productive cough/expectoration [36] were also found in sev-
eral previous studies, as well as pleura pain [36,40] and dysp-
noea [36,40,66]. Interestingly we were unable to identify any
use of sputum evaluation in ML classifiers of pneumonia
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classes. This may reflect difference in clinical practices in dif-
ferent regions.
Three ML methods: SVM; decision tree and LR, were
employed to facilitate comparison among commonly used
models for clinical classification problems with varying inter-
pretability. The selection was motivated by a desire to repre-
sent and compare methods which are frequently employed
in the literature for similar problems, in particular between
interpretable models. Comparison of performance between
existing studies is limited for several reasons: variation in
pneumonia reference standard; variation in subject popula-
tion and lack of standardized reporting of ML methods and
performance. The state-of-the-art studies to detect pneumo-
nia and/or COVID-19 Pneumonia are reported in Table 5. Of
the existing studies in the literature which utilized SVMs
[35,39,67], only one specified distinguishing pneumonia from
other diseases (as oppose to healthy patients). In this report
from Rother et al. 2015 [67], the authors reported a program
consisting of eight classifiers, with a sensitivity of 90% being
the only performance parameter reported. Perhaps due to it
is simplicity, LR has also proved a popular choice, Feng et al.
2020 [52] reported a high sensitivity of 100% with a specificity
of 78% and AUC of 93%when identifying COVD-19 pneumonia
based on symptoms and blood test results. Classification and
Regression Trees (CARTs) were used by De Santis et al. 2017
[42] (sensitivity of 38%, specificity of 97%) and Steurer et al.
2011 [40] (AUC of 90%) to classify pneumonia, however the lat-
ter failed to use any internal or external validation tech-
niques. Therefore, further analysis of the chosen methods
in relation to detection of pneumonia was required. The
results reported here support the use of simple, interpretable
models such as LR and decision tree, which were shown to
perform as well as or indeed better than linear SVM.
The tree-based model, which was considered most favour-
able for use in a clinical tool due to being easily understood,
was found to give the best performance with an AUC of
93%. In comparison, in 2018 Pervaiz et al. found the WHO
pneumonia symptomatic predictors for childhood pneumo-
nia: cough; difficulty breathing, fever, tachypnoea and chest
indrawing, to achieve an AUC of only 62% [36,47]. Reports of
models built using symptoms/signs alone are relatively rare
[42,67,68]. Nuzhat et al. reported high sensitivity and speci-
ficity (94%, 99%) in a logistic regression model using cough
and lower chest wall indrawing as predictors, however the
methodology lacked internal or external validation [68].
Rother et al. utilized an ensemble method, achieving a sensi-
tivity of 90%, in this case with the disadvantage of an uninter-
pretable final model [67]. More common has been to include
additional laboratory or clinical tests as predictors
[34,37,40,41,69,70], however, such techniques are costly, time
consuming and require specialist training, so would be
unavailable in low resource settings. Other studies in the lit-
erature have focused on employing image-based classifica-
tion to diagnosis pneumonia, in particular relating to
detecting cases of COVID-19 (Table 5). When the patients are
referred to hospital for suspected pneumonia, instrumental
investigations are certainly needed, including X-ray imaging.
In this case, image classification is most often approached
through deep learning methods and achieved high
Fig. 3 – ROC curves for tested models. Panel (A) Logistic Regression; (B) Decision Tree; (C) Linear Support Vector Machine. All
curves are reported based on test dataset which was held out from training.
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mance metrics above 90% (accuracy or AUC) [14,19-24]. For
instance, Li et al. reported an AUC of 95% for detecting CAP
from pulmonary CT scans [22], and Yue et al. achieved an
accuracy of over 90% for pneumonia detection in five different
convolutional neural networks (CNNs) using chest X-ray
images [14]. Whereas, Wang et al. [16] and Stephen at al.
[12] used a CNN-based model via chest X-ray images to detect
pneumonia from other medical conditions and/or healthy
patients by achieving higher performance than Sirazitdinov
et al. [13], that used an ensemble of two convolutional neural
networks for pneumonia localization from a large-scale chest
X-ray database. Another study [19] by Nahid et al. employed a
CNN model by also using chest X-ray images to detect
patients affected by pneumonia achieving over 97% accuracy.
A recent study by Musad et al. [18] employed radiomic fea-
tures extracted from chest X-ray images via a CNN method
which were then inputted to more traditional machine learn-
ing algorithms such as Random Forest Tree. However, they
achieved a lower classification accuracy (86.3%) to discrimi-
nate among healthy, bacterial pneumonia and viral pneumo-
nia categories. CNN was, in fact, often selected among the
studies reported in Table 5 to automatically detect viral pneu-
monia via imaging techniques. Only one study by Srivastava
et al. [20] applied CNN methodologies to assist medical
experts by providing a detailed and rigorous analysis of the
medical respiratory audio data for Chronic Obstructive Pul-
monary detection.
In order to reduce the time and complexity of developing
novel models from scratch, transfer learning has proved a
promising fast route to building high performance deep learn-
ing models. In particular regarding rapid development of
COVID-19 detection models, Hira et al. [21], Elgendi et al.
[23] and Brunese et al. [24] achieved an accuracy of 97.5%,
94% and 97% respectively, in detecting pneumonia from chest
X-rays using pre-trained models.
However, despite performing well on existing data, the
deep learning methods used in these studies are less prone
to be adopted in clinical settings due to low reliability and
trustfulness. Moreover, the studies employing imaging tech-
niques as predictors aimed to develop a diagnostic model,
whereas in this study we aimed at developing a classifier that
would have great value in assisting referrals of pneumonia,especially in LMICs. In fact, we presented a fully interpretable,
tree-based model taking symptoms and signs as inputs, that
can distinguish pneumonia patients with a similar perfor-
mance (above 90%) to image-based deep learning approaches.
Nevertheless, the high performance seen from these very
different ML approaches at both the initial patient referral
(based on symptoms) and hospital confirmation (based on
instrumental investigation through image analysis) high-
lighted the varied and exciting promise of AI for both referral
and diagnosis of pneumonia, which may contribute to allevi-
ating pressures on clinical staff and equipment especially in
LRS of LMICs. Most importantly, early symptomatic discrimi-
nation of pneumonia from bronchitis may avoid unnecessary
antibiotic treatments, helping to limit antibiotic resistance
and avoiding the onset of pneumonia complications that
may compromise patient treatment.
Among the studies aiming to develop tools for screening
and/or diagnosis of respiratory disease such as pneumonia,
bronchitis, asthma and COPD [44,45], the vast majority used
additional laboratory test results such as white blood cell
counts and sedimentation as well as symptoms. In practice,
carrying out such tests requires a high level of expertise and
costly facilities. Such requirements are not only challenging
in LRS, but also take time, therefore are not an ideal basis
for wide screening tools for rural areas in LMICs. Moreover,
Pervaiz et al. found no benefit to adding oxyhaemoglobin
levels to a ML model based on signs and symptoms alone to
predict radiographically confirmed pneumonia in children.
Furthermore, Naydenova et al. and Groeneveld et al. find that
addition of patient C-Reactive Protein (CRP) levels to models
based on symptoms, vital signs and age worsened perfor-
mance in classification of pneumonia. This falls into a wider
picture in which there is currently contention regarding the
use of biomarkers such as CRP or Procalcitonin (PCT) as indi-
cators for pneumonia [37,71], further research into their rele-
vance, in particular in LMICs, is necessary to justify their use
as predictors in diagnostic tools.
As well as demonstrating promising performance on exist-
ing data from a middle-income country, the model proposed
has the advantage of being easily interpreted. Such explain-
able AI models have several benefits, which increases their
clinical utility: trust in the system, guarding against bias,
passing regulatory requirements, verifying outputs and
Table 5 – State-of-the-art studies to detect pneumonia.
Studies focused on signs and symptoms




Pervaiz et al., 2018 [47] WHO criteria Pneumonia; Acute respiratory
illness
Logistic regression AUC: 62%
Groeneveld et al., 2019 [75] Runny nose absent; Feel ill; CRP
concentration
Pneumonia; Healthy Logistic regression AUC: 75%
Nuzhat et al., 2017 [68] Cough and lower chest wall
indrawing combined
Pneumonia; Healthy Logistic regression SEN: 94%
SPE: 99%
Naydenova et al., 2016 [76] Respiratory rate; Heart rate;
Temperature; Oxygen
saturation; Age
Pneumonia; Healthy Random Forest. Fivefold cross











Pneumonia; Other diseases Voting algorithm using SVM, aNN and
fuzzy logic
AUC: 99%
Steurer et al., 2011 [40] Chronic cough; Daily fever;
Dyspnoea; Respiratory rate;
Pleural friction rub; CRP
concentration
Pneumonia; No pneumonia CART, leave-one-out cross validation AUC: 90%
Rother et al., 2015 [77] Included symptoms such as:
Whistling/wheezing sounds
and drowsy
Pneumonia; Other diseases Program consisting of eight classifiers:
SVM, ANN, fuzzy rule-based, random
forest, LR, linear discriminant analysis,
naı̈ve Bayes, nearest neighbour,
ensemble
SEN: 90%
van Vugt et al., 2013 [78] Absence of runny nose;
Breathlessness; Crackles;
Diminishing breath sounds on
auscultation; Tachycardia;
Fever; CRP
Pneumonia; No pneumonia Multilevel logistic regression,
bootstrapping for internal validation
AUC: 77%
De Santis et al., 2017 [79] Abnormal chest auscultation Pneumonia; Other diseases CART SEN: 38%
SPE: 97%
Feng et al., 2020 [69] Combination of symptoms and
signs (age, heart rate, fever,





Logistic regression (LASSO). Data split





















































Table 5 – (continued)
tudies focused on signs and symptoms








Random fields probabilistic classifier SEN: 58–75%
tudies focused on imaging
ira et al., 2020 [21] Chest X-rays COVID-19; Viral
pneumonia; Bacterial
pneumonia; Healthy
Deep transfer learning, pre-trained
models. Nine convolutional neural
network-based architectures: AlexNet,
GoogleNet, ResNet-50, Se-ResNet-50,
DenseNet121, Inception V4, Inception









COVNet deep learning framework:
based on RestNet50. Training on 90%,
testing on 10% of data
AUC: 95%
runese et al., 2020 [24] Chest X-rays COVID-19; Pneumonia;
Pulmonary diseases;
Healthy
Deep transfer learning, network based
on VGG-16 (Visual Geometry Group
model). Data split: training, testing and
evaluation sets
ACC: 97%
lgendi et al., 2020 [23] Chest X-rays COVID-19; Viral
pneumonia; Bacterial
pneumonia
Pre-existing neural network DarkNet-
19. Data split: training 80%, validation
20%
ACC: 94.28%
ue et al., 2020 [14] Chest X-rays Pneumonia; Healthy Deep learning models, MobileNet (3  3
depthwise separable convolutions).
Data split for training and testing
ACC: 92.9%
irazitdinov et al., 2019 [13] Chest X-rays Normal; No lung
opacity/not Normal;
Lung opacity
Ensemble of two convolutional neural
networks, RetinaNet and Mask R-CNN.
Data split for training and testing,




ang et al., 2019 [16] Chest X-rays No pneumonia;
Pneumonia; Other
medical conditions
Deep learning, Cooperative CNN.




tephen et al., 2019 [12] Chest X-rays Pneumonia; Healthy CNN. Data split for training, testing and
validation
ACC: 93.73%
alsh et al., 2018 [15] CT scans Fibrotic lung disease;
Normal
Neural network Inception-ResNet-v2.16
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AI is not limited to symptom-based classifiers but extends
also into the field of image analysis. This is challenging for
deep learning, where it is not easy to follow the ‘decision
making’ process leading to the final classification, unless
specific tools for visualization of data significance are
employed [73,74]. In fact, there is evidence in the literature
of predictive deep learning models which are able to indicate
the areas of a chest X-ray which contributed most to disease
detection, which allows rapid identification of areas of inter-
est to a radiologist in a hospital setting [24].
The work detailed here is a proof of concept that a simple,
evidence-based ML model has the potential to perform well
using symptoms and signs alone as predictors. However, this
study comes with certain limitations. Firstly, the data driving
this work was collected in a European middle-income coun-
try, therefore, may be of limited utility in populations of
low-income countries (e.g., Sub-Saharan Africa), which
indeed experience the greatest burden from pneumonia. In
fact, pneumonia in Europe and pneumonia in Sub-Saharan
Africa may have different causes (e.g., ageing and pollution
vs Saharan desert dust), which may result in different symp-
toms. Furthermore, training of CHWs in low-income settings
in auscultation, spirometry or sputum evaluation may not be
easy, indeed equipment and expertise may not be available in
emergency rooms even in high-income regions. Whilst the
ML model reported in this study has the advantage of dis-
criminating pneumonia from bronchitis, determining of the
underlying pathogenesis and severity of pneumonia was
beyond the scope of this study. This will be an interesting
future avenue of research, as this information would be
highly valuable in identifying the best treatment for pneumo-
nia patients on an individual basis. Finally, in order to pro-
duce a clinical tool, it would be necessary to incorporate all
commonly presenting respiratory diseases, not only bronchi-
tis and pneumonia.
5. Conclusions
Correct referral and diagnosis of pneumonia is challenging
due to low specificity of symptoms, lack of widely available
diagnostic tests and varied clinical presentation amongst sub-
populations. In this study, we applied machine learning algo-
rithms to a dataset of 4344 patients (1500 bronchitis, 2844
pneumonia) containing information on subject population
characteristics, symptoms and laboratory test results. Feature
selection found 6 clinically relevant and easily interpreted
patient symptoms to be the best predictors of pneumonia in
this dataset. The best performing model that was able to dis-
tinguish pneumonia from bronchitis via sign and symptoms
was a decision tree, which achieved an AUC of 93%. The
robust, evidence-based design and ability to use symptoms
to distinguish pneumonia from a similar respiratory disease
(i.e., bronchitis) grants advantage for application in LMICs,
compared to previously reported models relying mainly on
instrumental tests and X-ray images. To be of most practical
use in resource limited settings, machine learning models
aiming at supporting disease screening, early diagnosis and
appropriate referral, must provide thorough reporting of
1300 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 4 1 ( 2 0 2 1 ) 1 2 8 8 –1 3 0 2methodology and performance and place emphasis on easily
evaluated attributes such as presenting clinical signs and
symptoms.
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